Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 255

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137749

Published: 2020

Journal Articles

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S Advani, MD, Madeline Waldron, PharmD, BCOP, Caitlin Siebenaller, PharmD, Jenna Thomas, Eric Parsons, RN, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139515

Published: 2020

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136342

Published: 2020

Journal Articles

A Single Center Review Evaluating Daratumumab Outcomes in Multiple Myeloma Patients at Monter Cancer Center/Northwell Health Cancer Institute

Chung H Chen, Chung-Shien Lee, Pharm.D, Samrah Ahmad, PharmD, BCPS, CACP, BCOP, Monique Hartley-Brown, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-143203

Published: 2020

Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143385

Published: 2020

Journal Articles

Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia

Ariel Denson, PharmD, Kristyn Y. DiSogra, PharmD, BCOP, Justin Arnall, PharmD, BCOP, Srinivasa R. Sanikommu, MD, Nilay A. Shah, MD, Brittany K. Ragon, MD, Thomas G. Knight, MD, Jing Ai, MDPhD, Michael R. Grunwald, MD, Belinda R Avalos, MD, Edward A Copelan, Aleksander L. Chojecki, MD

Blood (2020) 136 (Supplement 1): 14–17.

https://doi.org/10.1182/blood-2020-137250

Published: 2020

Journal Articles

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Jacinth Joseph, MD, Vanessa Wookey, MD, Brion Randolph, MD, Jason C. Chandler, MD, Dennis Marjoncu, PharmD, BCOP, Kori Holman, PharmD, Deniscer Peeler, LPN, Michelle Armstrong, NP, Yasser Khaled, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143049

Published: 2020

Journal Articles

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Alexander Coltoff, MD, Joseph G. Jurcic, MD, Peter Campbell, PharmD, BCOP, Daniel J. Lee, MD, Mark L Heaney, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD MS, Mark G. Frattini, MDPhD, George Vlad, PhD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-134237

Published: 2020

Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136182

Published: 2020

Journal Articles

Pharmacist Versus Physician Provider Management of Hydroxyurea Therapy for Polycythemia Vera (PERMANACE)

Benjamin Andrick, PharmD, Anupama Mathur, PharmD, BCOP, Tristan Maiers, PharmD, BCOP, Jove Graham, PhD, Joseph Vadakara, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142864

Published: 2020

Journal Articles

Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Angela Lee, PharmD, Frank Oley, Jr., PharmD, Mimi Lo, PharmD, BCPS, BCOP, Richard Fong, PharmD, BCOP, Mary McGann, PharmD, Ila Saunders, PharmD, BCOP, Shanna Block, PharmD, BCOP, Anjlee Mahajan, MD, Tiffany Pon, PharmD, BCPS

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-138635

Published: 2020

Journal Articles

Efficacy, Safety and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma: A Single Center Experience

Jessica Marini, PharmD, Andy Maldonado, PharmD, BCOP, Erin R Weeda, PharmD, BCPS, Hamza Hashmi, MD, Amarendra K. Neppalli, MD, Kathy Edwards, PharmD, BCPS, BCOP, HRM

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-143137

Published: 2020

Journal Articles

Medical Simulation in Relapsed Follicular Lymphoma Improves Clinical Decision Making of Hematologists/Oncologists

Lauren Willis, PharmD, Donna Topping, PharmD, BCOP, Sarah Atwood, MPH, Jonathon B. Cohen, MDMS

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136084

Published: 2020

Journal Articles

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Gabriela Sanchez-Petitto, MD, Olga Goloubeva, PhD MSc, James Childress, MD, Tahreem Iqbal, MD, Jack Masur, MD, Max An, BS, Safwan Muhammad, MD, Justin Lawson, PharmD BCOP, Jasmin Sahbaz, MD, Brian Barr, MD, Vu H. Duong, MD, Jennie Y. Law, MD, Ashkan Emadi, MD, PhD, Maria R. Baer, MD, Sandrine Niyongere, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138534

Published: 2020

Journal Articles

Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Yazan F. Madanat, MD, Hetalkumari Patel, PharmD, BCOP, Omik Patel, PharmD, BCOP, Jingsheng Yan, PhD, Jude Khatib, MD, Madhuri Vusirkala, MD, Suleyman Y Goksu, MD, Chul Ahn, PhD, Prapti A. Patel, MD, Robert H. Collins, MD, Stephen Chung, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-139794

Published: 2020

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

Journal Articles

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Jeffrey Marsal, BS, Rahul Banerjee, MD, Chiung-Yu Huang, PhD, Mimi Lo, PharmD, BCPS, BCOP, Vanessa E Kennedy, MD, Shagun Arora, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Sandy W. Wong, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138618

Published: 2020

Journal Articles

Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Mark B. Geyer, MD, Amber C. King, PharmD, BCOP, Justin C. O'Brien, Jae H. Park, MD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-137016

Published: 2020

Journal Articles

Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

Maximilian Stahl, MD, Kamal Menghrajani, MD, Andriy Derkach, PhD, Alexander Chan, MD, Wenbin Xiao, MD PhD, Jacob L Glass, MDPhD, Amber C. King, PharmD, BCOP, Anthony Daniyan, MD, Christopher Famulare, MS, Bernadette M. Cuello, BSN, MSN, NP, RN, Omar Abdel-Wahab, MD, Ross L. Levine, MD, Aaron D Viny, MDMS, Eytan M. Stein, MD, Mikhail Roshal, MD PhD, Martin S. Tallman, MD, Aaron D Goldberg, MDPhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137815

Published: 2020

Journal Articles

Evaluation of Dose-Adjusted EPOCH-R Compared with R-CHOP for the Treatment of High-Risk, Aggressive B-Cell Lymphomas: A Single-Center Experience

Sarah J. Rockwell, BS,PharmD, Katherine A. Richter, PharmD, MBA, BCOP, Ryan J. Caddell, PharmD, BCOP, Julio C. Chavez, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140085

Published: 2020

NARROW

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

A Single Center Review Evaluating Daratumumab Outcomes in Multiple Myeloma Patients at Monter Cancer Center/Northwell Health Cancer Institute

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Pharmacist Versus Physician Provider Management of Hydroxyurea Therapy for Polycythemia Vera (PERMANACE)

Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Efficacy, Safety and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma: A Single Center Experience

Medical Simulation in Relapsed Follicular Lymphoma Improves Clinical Decision Making of Hematologists/Oncologists

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

Evaluation of Dose-Adjusted EPOCH-R Compared with R-CHOP for the Treatment of High-Risk, Aggressive B-Cell Lymphomas: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only